Samsara BioCapital’s Verona Pharma VRNA Stock Holding History

Samsara BioCapital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97,625	Closed	-$4.53M	–	43
2024 Q4	$4.53M	Sell	97,625 -97,600	-50%	-$3.66M	0.62%	24
2024 Q3	$5.62M	Sell	195,225 -152,275	-44%	-$3.75M	1.08%	21
2024 Q2	$5.02M	Hold	347,500	–	–	1.05%	22
2024 Q1	$5.59M	Hold	347,500	–	–	0.87%	22
2023 Q4	$6.91M	Hold	347,500	–	–	1.07%	18
2023 Q3	$5.66M	Hold	347,500	–	–	1.73%	16
2023 Q2	$7.35M	Sell	347,500 -347,501	-50%	-$7.41M	1.29%	14
2023 Q1	$14M	Hold	695,001	–	–	2.88%	9
2022 Q4	$18.2M	Sell	695,001 -243,889	-26%	-$3.25M	3.91%	5
2022 Q3	$9.6M	Sell	938,890 -172,222	-15%	-$1.45M	2.24%	10
2022 Q2	$4.66M	Hold	1,111,112	–	–	1.24%	21
2022 Q1	$5.54M	Hold	1,111,112	–	–	1.4%	17
2021 Q4	$7.47M	Hold	1,111,112	–	–	1.45%	17
2021 Q3	$6.09M	Hold	1,111,112	–	–	0.96%	25
2021 Q2	$7.27M	Hold	1,111,112	–	–	0.9%	21
2021 Q1	$9.29M	Hold	1,111,112	–	–	1.71%	17
2020 Q4	$7.78M	Hold	1,111,112	–	–	0.78%	13
2020 Q3	$6.93M	Buy	1,111,112 +1,067,656	+2,457%	+$7.38M	1.93%	13
2020 Q2	$203K	Buy	+43,456	New	+$201K	0.07%	32

Other funds holding VRNA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Samsara BioCapital's VRNA Position: Q1 2025 in Review

Samsara BioCapital sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 97,625 shares — an estimated $4.53M sold.

Samsara BioCapital first reported a position in VRNA in Q2 2020 and held it in 19 quarters. The position peaked at $18.2M in Q4 2022. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

Samsara BioCapital reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
Samsara BioCapital sold 97,625 Verona Pharma shares in Q1 2025, an estimated $4.53M.
Samsara BioCapital first reported a position in Verona Pharma in Q2 2020 and held it in 19 quarters.
Samsara BioCapital's Verona Pharma position peaked at $18.2M in Q4 2022.
258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.